GentiBio
GentiBio, Inc. is a biotherapeutics company developing engineered regulatory T cells (Tregs) therapies for immunology.
2
Funding Rounds
$177.0m
Money raised
Funding
Funding series
Funding Series Analysis
The company GentiBio has raised a total of $177m in funding over 2 rounds.
Key Insights:
- GentiBio Series A round, August 2021: $157m
- GentiBio Seed round, August 2020: $20m
GentiBio Series A round, August 2021
$157m
GentiBio Seed round, August 2020
$20m
Industries
GentiBio is active in the following industries: